MACH-1
Live / Applied — Second extension granted (statement of use) (as of 23 Mar 2026)
What this means for you
Not registered yet, but its 15 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98648791
- Mark type
- Stylized text
- Filed
- 15 Jul 2024
- Published for opposition
- 04 Mar 2025
- Attorney of record
- Connie Ellerbach
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; vaccine preparations; medical preparations for the treatment of autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes; pharmaceutical preparations and substances for the treatment of autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes; chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of diseases affecting mucosal tissues, the immune system, respiratory tissues; chemical preparations for pharmaceutical purposes, namely, for autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes; chemical preparations for medical purposes, namely, for autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes
- Class 042 — Scientific and technological services: Research and development of vaccines; research and development of medicines; medical research; scientific research; clinical research; all in the field of autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes, immunotherapy
- Class 044 — Medical, beauty and agricultural services: Medical services; medical testing for treatment purposes; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical evaluation services of autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes; medical treatment of autoimmune diseases, infectious diseases, respiratory diseases, mucosal diseases, multiple sclerosis, type 1 diabetes
Owner
- Orlance, Inc., Seattle, WA, US
- Orlance, Inc., Seattle, WA, US
Prosecution history
- 24 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Mar 2026 — SOU EXTENSION 2 GRANTED
- 23 Mar 2026 — SOU EXTENSION 2 FILED
- 23 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 14 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Aug 2025 — SOU EXTENSION 1 GRANTED
- 13 Aug 2025 — SOU EXTENSION 1 FILED
- 13 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 29 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Mar 2025 — PUBLISHED FOR OPPOSITION
- 04 Mar 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 06 Feb 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 06 Feb 2025 — EXAMINER'S AMENDMENT ENTERED
- 06 Feb 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED